Conclusions about I-O and 2 Line
Patients with mUC that have progressed to previous platinum-containing
regimens have poor prognosis, with few treatment options
Increasing evidence suggests that checkpoint inhibitors are an effective
treatment strategy in these context
We currently have Phase I-III evidence to support this approach that most
likely will change the natural history of mUC
Yet, a substantial proportion of patients will not benefit from this strategy
and efforts should be devoted to uncover valid predictive tools
